SCHEMBL13429255

SCHEMBL13429255

O=c1cc(Oc2cccc(N3CCOCC3)c2)c2ccccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
KIF11 P52732 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 2/20 0.46
HPGD P15428 2/20 0.46
KMT2A Q03164 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PIK3CG P48736 2/20 0.44
PDGFRB P09619 1/20 0.44
FGFR1 P11362 1/20 0.44
FLT1 P17948 1/20 0.44
KDR P35968 1/20 0.44
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BRAF P15056 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429232 0.90 KIF11 (0.47) ALDH1A1KIF11KDM4EMEN1HPGD
SCHEMBL3225576 0.86 KIF11 (0.47) ALDH1A1KIF11KDM4EKMT2AMAPT
SCHEMBL3221527 0.86 KIF11 (0.54) ALDH1A1KIF11KDM4EMEN1HPGD
SCHEMBL13429235 0.82 CNR2 (0.51) MAPTPIK3CA
SCHEMBL13429335 0.80 PIK3CB (0.45) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL13429239 0.79 KDM4E (0.53) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL13429015 0.78 SMN1; SMN2 (0.54) ALDH1A1KIF11MAPTPDGFRBFGFR1
SCHEMBL13429341 0.78 HTR1A (0.45) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL3224936 0.77 MAOB (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL2008835 0.77 HPGD (0.54) ALDH1A1KDM4EMEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA ALDH1A1 2884/4885KIF11 2758/4885KDM4E 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.